Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Refocusing ZymoGenetics Cuts Staff, Seeds Pipeline Of Private Startup Firm

This article was originally published in The Pink Sheet Daily

Executive Summary

In a deal that resembles a spin-out but is termed an arms-length transaction, ZymoGenetics transfers eight preclinical programs to Seattle Life Sciences for future considerations, including an equity stake.

You may also be interested in...



With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics

Bristol-Myers Squibb launched its $885-million tender offer for Seattle biotech ZymoGenetics Sept. 10, with two major shareholders representing more than a third of the biotech's shares already on board. The acquisition would give Bristol full rights to a mid-stage interferon treatment for hepatitis C that it currently shares with ZymoGenetics.

With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics

Bristol-Myers Squibb launched its $885-million tender offer for Seattle biotech ZymoGenetics Sept. 10, with two major shareholders representing more than a third of the biotech's shares already on board. The acquisition would give Bristol full rights to a mid-stage interferon treatment for hepatitis C that it currently shares with ZymoGenetics.

From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics

Ever since its pure-play biopharma strategy went into effect, Bristol-Myers Squibb has preferred buying biotechs it knows well. Hepatitis C development partner ZymoGenetics is no exception.

Related Content

Topics

UsernamePublicRestriction

Register

PS069510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel